We are live on
!
Find out more
SI
Sofinnova Investments Portfolio holdings
AUM
$2.63B
1-Year Est. Return
117.41%
This Fund
S&P 500
This Quarter
Est. Return
-7.85%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$394M
(-23%)
Cap. Flow
-$88.3M
Cap. Flow
% of AUM
-6.7%
Top 10 Holdings %
Top 10 Hldgs %
63.8%
Holding
83
New
13
Increased
13
Reduced
16
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$114M |
| 2 |
AstraZeneca
AZN
|
+$33.2M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$22.5M |
| 4 |
Zoetis
ZTS
|
+$21.1M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$42.2M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$26.3M |
| 3 |
Align Technology
ALGN
|
+$25.1M |
| 4 |
Heron Therapeutics
HRTX
|
+$21.4M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$20.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SYBX
51
DELISTED
Synlogic
SYBX
| $1.38M | 0.1% |
38,331
| – | – |
|
52
CALL
Geron
GERN
$924M
| $1.36M | 0.1% |
+1,000,000
| New | +$1.11M |
|
53
Amylyx Pharmaceuticals
AMLX
$2.15B
| $1.28M | 0.1% |
+100,000
| New | +$2.26M |
|
54
PDS Biotechnology
PDSB
$38.6M
| $883K | 0.07% |
142,635
| – | – |
|
55
MiNK Therapeutics
INKT
$52.5M
| $745K | 0.06% |
33,100
-1,450
| -4% | -$43.6K |
|
|
FUSN
56
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $607K | 0.05% |
78,066
| – | – |
|
57
Insulet
PODD
$11.7B
| $284K | 0.02% |
1,066
| – | – |
|
58
PTC Therapeutics
PTCT
$6.12B
| $130K | 0.01% |
3,480
-128,968
| -97% | -$4.97M |
|
59
Insmed
INSM
$22.7B
| $126K | 0.01% |
5,368
-436,405
| -99% | -$10.1M |
|
|
60
Heron Therapeutics
HRTX
$91.6M
| $63K | ﹤0.01% |
11,060
-2,922,291
| -100% | -$21.4M |
|
|
61
AbbVie
ABBV
$469B
| – | – |
-312,018
| Closed | -$42.2M |
|
|
AGEN
62
Agenus
AGEN
$261M
| – | – |
-99,915
| Closed | -$6.32M |
|
|
63
Align Technology
ALGN
$12.4B
| – | – |
-38,159
| Closed | -$25.1M |
|
64
Aligos Therapeutics
ALGS
$26.2M
| – | – |
-5,112
| Closed | -$1.52M |
|
65
PUT
Axsome Therapeutics
AXSM
$12.2B
| – | – |
-100,000
| Closed | -$3.78M |
|
|
66
BioCryst Pharmaceuticals
BCRX
$2.42B
| – | – |
-1,510,473
| Closed | -$20.9M |
|
|
BPMC
67
DELISTED
Blueprint Medicines
BPMC
| – | – |
-245,182
| Closed | -$26.3M |
|
68
Celldex Therapeutics
CLDX
$2.77B
| – | – |
-271,533
| Closed | -$10.5M |
|
69
Edwards Lifesciences
EW
$48.3B
| – | – |
-1,406
| Closed | -$182K |
|
70
InflaRx
IFRX
$242M
| – | – |
-1,161,736
| Closed | -$5.53M |
|
71
iRhythm Holdings
IRTC
$3.82B
| – | – |
-168,882
| Closed | -$19.9M |
|
72
CALL
Kura Oncology
KURA
$831M
| – | – |
-175,000
| Closed | -$2.45M |
|
|
73
Kura Oncology
KURA
$831M
| – | – |
-369,173
| Closed | -$5.17M |
|
74
CALL
NovoCure
NVCR
$1.92B
| – | – |
-50,000
| Closed | -$3.75M |
|
75
uniQure
QURE
$2.46B
| – | – |
-495,025
| Closed | -$10.3M |
|
Similar funds
WWM
ACI
LOAMS
IA
WCA
ACM
NIG
WBG
Sofinnova Investments's Q1 2022 Portfolio in Review
As of Q1 2022, Sofinnova Investments held 83 positions worth $1.32B, down 23% from $1.71B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Sofinnova Investments withdrew a net $88.3M in Q1 2022, closing 22 positions and reducing 16 holdings. Its most notable exit was AbbVie, an estimated $42.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier.
Against the trend, Sofinnova Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $97.8M.
- Sofinnova Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 5,573,949 shares worth $97.8M.
- Sofinnova Investments added most to United Therapeutics in Q1 2022, an estimated $13.2M increase.
- Sofinnova Investments's biggest Q1 2022 reduction was Heron Therapeutics, cutting an estimated $21.4M.
- Sofinnova Investments fully exited AbbVie in Q1 2022, selling an estimated $42.2M.
- Sofinnova Investments's ten largest holdings make up 64% of its $1.32B portfolio in Q1 2022.
- Sofinnova Investments opened 13 new positions and closed 22 in Q1 2022.
- Sofinnova Investments's portfolio value fell 23% quarter-over-quarter to $1.32B.
Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.